The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1

AIDS

Volumn 13, Issue 16, 1999, Pages 2239-2250

  Moore, Katy H P ^a   Barrett, Jo E ^c   Shaw, Shuching ^a   Pakes, Gary E ^a   Churchus, Richard ^c   Kapoor, Anu ^a   Lloyd, Judy ^b   Barry, Michael G ^b   Back, David ^b  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Clinical Pharmacology Glaxo Wellcome Inc ^*

Author keywords

Lamivudine; Pharmacokinetics; Phosphorylation

Indexed keywords

CD4 ANTIGEN; DRUG METABOLITE; LAMIVUDINE; LAMIVUDINE DIPHOSPHATE; LAMIVUDINE MONOPHOSPHATE; PHOSPHATE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; LYMPHOCYTE COUNT; MALE; MASS SPECTROMETRY; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0001024860     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199911120-00006     Document Type: Article

References (47)

1. 1. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
2. 2. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT 3TC combination therapy. Science 1995, 269: 696-699.
3. 3. Tisdale M, Kemp SD, Parry NR, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
4. 4. Soudeyns H, Yao XJ, Gao Q, et al. Anti-human immunodeficiency virus type I activity and in vitro toxicity of 2′-deoxy3′thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991, 35:1386-1390.
5. 5. Coates JA, Cammack N, Jenkinson HJ, et al. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992, 36:202-205.
6. 6. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
7. 7. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
8. 3. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract LB7].
9. 3 - 60-week follow-up. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 383].
10. 10. Baruch A, Mastrodonato-Delora P, Schnipppr E, Salgo M. Efficacy and safety of triple combination therapy with Invirase (saquinavir/SQ/HIV protease inhibitor), Epivir (3TC/lamivudine) and Retrovir (ZDV/zidovudine) in HIV-infected patients. XI Conference on AIDS. Vancouver, July 1996 [abstract Mo.B172].
11. 11. Markowitz M, Cao Y, Hurley A, et al. Triple therapy with AZT and 3TC in combination with nelfinavir mesylate in 12 antiretroviral-naïve subjects chronically infected with HIV-1. XI Conference on AIDS. Vancouver, July 1996 [abstract LB.B 6031].
12. 12. Hoen B, Harzic M, Dumon C, et al. Efficacy of zidovudine, lamivudine, and ritonavir combination in patients with symptomatic primary HIV-1 infection: the ANRS 053/53B trial. Can eradication be obtained? Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 524].
13. 13. Culick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection. JAMA 1998, 280:35-41.
14. 14. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
15. 15. Swartz MN. Mitochondria! toxicity - new adverse drug effects. N Engl J Med 1995, 333:1146-1148.
16. 16. Hart GJ, Orr DC, Penn CR, et al. Effects of (-)-2′deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases α, β, and γ. Antimicrob Agents Chemother 1992, 36:1688-1694.
17. 17. Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997, 53:657-680.
18. 18. Cammack N, Rouse P, Marr CLP, et al. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol 1992, 43:2059-2064.
19. 19. Kewn S, Veal GJ, Hoggard PG, Barry MG, Back DJ. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem Pharmacol 1997, 54:589-595.
20. 20. Gray NM, Marr CLP, Penn CR, Cameron JM, Bethell RC. The intracellular phosphorylation of (-) 2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase γ. Biochem Pharmacol 1995, 50:1043-1051.
21. 21. Robbins BL, Tran TT, Pinkerton Jr FH, et al. Measurements of intracellular lamivudine and zidovudine metabolites in peripheral blood mononuclear cells (PBMCs) from HIV-treated patients. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 361].
22. 22. Sommadossi J-P, Valantin MA, Zhou X-J, et al. Intracellular phosphorylation of stavudine (d4T) and 3TC correlates with their antiviral activity in naive and zidovudine (ZDV) experienced HIV-infected patients. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 362].
23. 23. Wring SA, O'Neill RM, Williams JL, et al. The production and evaluation of a radioligand and antiserum for the radioimmunoassay of subnanogram per millilitre concentrations of lamivudine. J Pharmaceut Biomed Anal 1994, 12:1573-1583.
24. 24. Conover WJ. Practical Non-Parametric Statistics: 2nd Edn. Wiley, New York; 1980: 223-227, 288-290.
25. 25. Koch GG. The use of nonparametric methods in the statistical analysis of the two period change-over design. Biometrics 1972, 28:577-584.
26. 26. Back DJ, Hoggard PG, Gibbons SE, et al. Zidovudine (ZDV) phosphorylation determined at intervals over 12 months in naïve and antiretroviral experienced HIV+ patients. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract LB10].
27. 27. Rodman JH, Robbins B, Flynn PM, et al. A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients. J Infect Dis 1996, 174:490-499.
28. 28. Van't Wout AB, Ran LJ, De Jong MD, et al. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. J Clin Invest 1997, 100:2325-2332.
29. 29. Hoggard PG, Veal GJ, Wild MJ. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother 1995, 39:1376-1378.
30. 30. Turriziani O, Antonelli C, Verri A, et al. Alteration in thymidine kinase activity in cells treated with an antiviral agent. J Biol Regul Homeost Agents 1995, 9:47-51.
31. 31. Hill MD, Miles S, Gomperts E, et al. Decreased activation of zidovudine (AZT) in peripheral blood lymphocytes from patients with AIDS chronically treated with AZT. VII International Conference on AIDS, Florence, June 1991 [TH.B.36].
32. 32. Avramis VI, Kwock R, Solozano MM, et al. Evidence of in vitro development of drug resistance to azidothymidine in T lymphocytic leukemia cell lines (Jurkat E6-1/AZT 100) and in pediatric patients with HIV-1 infection. J Acquir Immune Defic Syndr 1993, 6:1287-1296.
33. 33. Barry MG, Khoo SH, Veal GJ, et al. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 1996, 10:1361-1367.
34. 34. Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994, 8:F1-F5.
35. 35. Robbins BL, Rodman J, McDonald C, et al. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1994, 38:115-121.
36. 36. Peter K, Gambertoglio JG. Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1996, 60:168-176.
37. 37. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir (IDV), zidovudine (ZDV), and lamivudine (3TC): three-year follow-up. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 388].
38. 38. Stretcher BN, Pesce AJ, Frame PT, et al. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994, 38:1541-1547.
39. 39. Stretcher BN, Pesce AJ, Hurtubise PE, et al. Pharmacokinetics of zidovudine phosphorylation in patients with the human immunodeficiency virus. Ther Drug Monit 1992, 14:281-285.
40. 40. Stretcher BN, Pesce AJ, Murray JA, et al. Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations. Trier Drug Monit 1991, 13:325-331.
41. 41. Pluda JM, Cooley TP, Montaner JSG, et al. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995; 171:1438-1447.
42. nd Edn. Edited by Westley GJ. Montvale, New Jersey: Medical Economics Company, Inc., 1998:768-772.
43. 43. Ho HT, Hitchcock MJM. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog actively inhibits against human immunodeficiency virus. Antimicrob Agents Chemother 1989, 33:844-849.
44. 44. Zhu Z, Ho HT, Hitchcock MJ, Sommadossi J-P. Cellular phar′ macology of 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) in human peripheral blood mononuclear cells. Biochem Pharmacol 1990, 39:R14-R19.
45. 45. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986, 83:8333-8337.
46. 46. Lavie A, Schlichting I, Vetter IR, Konrad M, Reinstein J, Goody RS. The bottleneck in AZT activation. Nature Med 1997, 3:922-924.
47. 47. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 1996, 40:1514-1519.